According to new research, the financial crisis at the NHS has caused cutbacks on critical clinical trials conducted with drug companies on new medicines. Financially challenged hospitals are redirecting nurses away from drug research to make up for the shortfall in doctors and nurses doing clinical work with patients, according to a report in research
Today Johnson & Johnson announced a collaboration between Johnson & Johnson Services, Inc. and a subsidiary of HP Inc. The partnership will be focused on using 3D printing technologies to create better healthcare outcomes at a reduced cost. By working together, the companies plan to combine their scientific, clinical, material science and technological expertise to
Pfizer is reportedly gearing up to test a combination of three cancer drugs in human trials next year. According to the Financial Times, the trial, which will be one of the first to test a trio of immunotherapies, will monitor the safety and efficacy of the combination in patients with solid cancers. Although current immunotherapies
The EU’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of potentially the first corrective ex vivo gene therapy for children anywhere in the world. GlaxoSmithKline received the green light from the CHMP for Strimvelis as a treatment for the rare disease ADA-SCID. Which is combined immunodeficiency due to adenosine deaminase
GlaxoSmithKline (GSK) and the UK’s Medical Research Council (MRC) will be collaborating in an open innovation research initiative aiming to improve scientists’ understanding of inflammatory diseases. The Experimental Medicine Initiative to Explore New Therapies (EMINENT) network will bring together researchers from the Universities of Cambridge, Glasgow, Newcastle, Imperial College London and UCL, with GSK scientists
Following weeks of speculation, Teva yesterday made a $40-billion-bid for Mylan NV. Teva has offered $82 per Mylan share in a 50/50 cash/stock transaction valued at just over $40 billion. However, the reaction so far to the news suggests that Teva would need to improve on their bid for it to be accepted. S&P Capital
Johnson & Johnson have announced positive results for the first quarter of 2015, beating earnings expectations. However, the company has been forced to lower their full-year expectations for 2015 from $6.12-$6.27 per share to $6.04-$6.19, as a result of exchange rates with a strong US dollar. The negative currency effect is expected to continue to
Takeda has announced that they have signed a deal with ImmunoGen for two anticancer targets. Takeda signed the agreement with ImmunoGen through its subsidiary Millennium Pharmaceuticals. The agreement, which grants Takeda exclusive rights to use ImmunoGen’s ADC technology for anticancer therapeutics, could be worth up to $230m. Specifically, the Japanese pharmaceutical company has licensed exclusive
Bristol-Myers Squibb have announced that they will be acquiring Flexus Biosciences in an agreement worth up to $1.25 billion. Flexus are a biotechnology company which specialises in the discovery, development, and commercialisation of small-molecule cancer immunotherapies targeting regulatory T cells. The acquisition will involve an $800 million upfront payment, giving Bristol-Myers Squibb full rights to
Roche has today announced that they have acquired Germany’s Signature Diagnostics. Signature Diagnostics were a privately-held translational oncology and genomics company, based in Potsdam, Germany. The acquisition is the fifth deal that Roche has made within the past year, aimed at building their molecular diagnosis business. Signature Diagnostics focuses on developing large blood plasma and
